Form 4: Alkermes Executive Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Alkermes EVP Craig C. Hopkinson exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Summary
- Craig C. Hopkinson, EVP of R&D and Chief Medical Officer at Alkermes plc, executed transactions involving the company's ordinary shares on November 11, 2024.
- Hopkinson exercised 43,058 stock options at a price of $20.03 per share.
- He then sold 58,996 ordinary shares at a weighted average price of $30.0796, with individual sales ranging from $30.00 to $30.20.
- These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on December 14, 2023.
- Following these transactions, Hopkinson directly owns 83,300 ordinary shares and 129,174 stock options.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative in itself. The use of a 10b5-1 plan suggests a planned and expected transaction.
Industry Context
This is a routine filing related to executive stock transactions and is common in publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology and pharmaceutical sectors like Amgen, Biogen, and Gilead Sciences.
- These plans allow executives to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
- The reported transactions are consistent with typical executive compensation practices, where stock options are granted and subsequently exercised and sold.
Stakeholder Impact
- The transactions may have a minor impact on the stock price due to the volume of shares sold, but this is likely to be minimal given the pre-planned nature of the trades.
- The transactions do not have a direct impact on employees, customers, or suppliers.
Key Dates
| Date | Description |
|---|---|
| 12/14/2023 | Date the Rule 10b5-1 trading plan was adopted by Craig C. Hopkinson. |
| 11/11/2024 | Date of the stock option exercise and share sale transactions. |
| 11/12/2024 | Date the Form 4 was signed. |
| 02/20/2030 | Expiration date of the employee stock options. |
Keywords
Alkermes, stock options, share sale, Rule 10b5-1, insider trading, executive compensation, ALKS, Craig C. Hopkinson
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.